Man Group PLC Immuneering Corp Transaction History

Man Group PLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.62 - $2.47 $220 - $335	136 Added 0.99%	13,914 $30,000
Q3 2024 Nov 14, 2024	BUY	$1.03 - $3.21 $14,191 - $44,227	13,778 New	13,778 $34,000
Q1 2023 May 15, 2023	SELL	$3.78 - $10.38 $23,413 - $64,293	-6,194 Reduced 33.72%	12,174 $118,000
Q4 2022 Feb 14, 2023	BUY	$4.09 - $15.0 $75,125 - $275,520	18,368 New	18,368 $89,000

14.5M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $169M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.